The Use of Erythropoietin in Liver Regeneration in Pigs after Partial Hepatectomy
Henrique de Aguiar Wiederkehr1*, Caroline Aragão de Carvalho1, Julio Cesar Wiederkehr2, Ricardo Ribeiro Gama3, Eros Luiz de Sousa4, Teresa Cristina Cavalcanti5, Taíse Fuchs6, Barbara de Aguiar Wiederkehr1, Lucas Mansano Sarquis1
1Faculdade Evangélica do Paraná, Curitiba, Paraná, Brazil.
2Department of Surgery, Federal University of Paraná, Curitiba, Paraná, Brazil.
3Department of Experimental Surgery, Faculdade Evangélica do Paraná, Curitiba, Paraná, Brazil.
4Department of Veterinary Medicine, Faculdade Evangélica do Paraná, Curitiba, Paraná, Brazil.
5Department of Pathology, Federal University of Paraná, Curitiba, Paraná, Brazil.
6Department of Veterinary Anesthesiology, Faculdade Evangélica do Paraná, Curitiba, Paraná, Brazil.
DOI: 10.4236/ss.2015.611074   PDF   HTML   XML   4,593 Downloads   5,282 Views  


A partial hepatectomy is a surgical procedure performed during the living-donor liver transplantation and sometimes the only option for patients with hepatocarcinoma. However the remnant liver after the hepatectomy is still a major concern. Therefore, the process of liver regeneration has been a constant theme of study in order to optimize this process. Erythropoietin, a hormone produced by the kidney and involved in protecting organs like heart, liver and kidney itself against injuries can be one of these factors that could accelerate the liver regeneration. This study aims to observe if erythropoietin can accelerate the process of liver regeneration after partial hepatectomy in pigs. Methods: 8 pigs were classified into 2 groups of 4 pigs each: the control group and the test group. The animals in the first group underwent an application of saline solution subcutaneous on the day before the hepatectomy. Instead of saline solution, the test groups received a subcutaneous injection of 200 UI/lg of recombinant erythropoietin also on the day before the surgical procedure. After 7 days since the hepatectomy, in each animal the liver was biopsied in two regions, one next to the hepatectomy section and other far from it. The liver regeneration was analyzed using Ki-67. Results: Pigs from control group presented the following results: Control pig I: 30% of regeneration in the hepatectomy section and 10% in the region far from it; control pig II 24% and 4%; control pig III 27% and 7%. The test group presented no significant liver regeneration since Ki-67 could not identify cell proliferation in neither the biopsied areas. Conclusion: Since the number of pigs was not statistically significant, we could not conclude any further hypothesis. We strong believe that enhancing the number of pigs and testing different doses, we will be able to reach further conclusions.

Share and Cite:

Wiederkehr, H. , de Carvalho, C. , Wiederkehr, J. , Gama, R. , de Sousa, E. , Cavalcanti, T. , Fuchs, T. , Wiederkehr, B. and Sarquis, L. (2015) The Use of Erythropoietin in Liver Regeneration in Pigs after Partial Hepatectomy. Surgical Science, 6, 518-526. doi: 10.4236/ss.2015.611074.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Gul, M., Comert, M., Cakmak, G.K., Kertis, G., Ugurbas, E. and Oner, M.O. (2013) Effect of Erythropoietin on Liver Regeneration in an Experimental Model of Partial Hepatectomy. International Journal of Surgery (London, England), 11, 59-63.
[2] Belghiti, J., Hiramatsu, K., Benoist, S., Massault, P., Sauvanet, A. and Farges, O. (2000) Seven Hundred Forty-Seven Hepatectomies in the 1990s: An Update to Evaluate the Actual Risk of Liver Resection. Journal of the American College of Surgeons, 191, 38-46.
[3] Jarnagin, W.R., Gonen, M., Fong, Y., DeMatteo, R.P., Ben-Porat, L., Little, S., Corvera, C., Weber, S. and Blumgart, L.H. (2002) Improvement in Peri-Operative Outcome after Hepatic Resection: Analysis of 1,803 Consecutive Cases over the Past Decade. Annals of Surgery, 236, 397-406.
[4] Garcea, G. and Maddern, G.J. (2009) Liver Failure after Major Hepatic Resection. Journal of Hepato-Biliary-Pancreatic Surgery, 16, 145-155.
[5] Liu, X., Xie, W., Liu, P., Duan, M., Jia, Z., Li, W. and Xu, J. (2006) Mechanism of Cardioprotection of rhEPO Pretreatment on Suppressing the Inflammatory Response in Ischemia-Reperfusion. Life Sciences, 78, 2255-2264.
[6] Bennett, C.L., Cournoyer, D., Carson, K.R., Rossert, J., Luminari, S., Evens, A.M., Locatelli, F., Belknap, S.M., McKoy, J.M., Lyons, E.A., Kim, B., Sharma, R., Costelo, S., Toffelmire, E.B., Wells, G.A., Messner, H.A., Yarnold, P.R., Trifilio, S.M., Raisch, D.W., Kuzel, T.M., Nissenson, A., Lim, L.C., Tallman, M.S. and Casadevall, N. (2005) Long-Term Outcome of Individuals With Pure Red Cell Aplasia and Antierythropoietin Antibodies in Patients Treated With Recombinant Epoetin: A Follow-Up Report from the Research on Adverse Drug Events and Reports (RADAR). Project. Blood, 106, 3343-3347.
[7] Cohen, V., Jellinek, S.P., Teperikidis, L., Berkovits, E. and Goldman, W.M. (2007) Room-Temperature Storage of Medications Labeled for Refrigeration. American Journal of Health-System Pharmacy, 64, 1711-1715.
[8] Corbo, D.C., Suddith, R.L., Sharma, B. and Naso, R.B. (1992) Stability, Potency, and Preservative Effectiveness of Epoetin Alfa after Addition of a Bacteriostatic Diluent. American Journal of Hospital Pharmacy, 49, 1455-1458.
[9] Corwin, H.L., Gettinger, A., Fabian, T.C., May, A., Pearl, R.G., Heard, S., An, R., Bowers, P.J., Burton, P., Klausner, M.A. and Corwin, M.J. (2007) Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. The New England Journal of Medicine, 357, 965-976.
[10] Greif, F., Ben-Ari, Z., Taya, R., Pappo, O., Kurtzwald, E., Cheporko, Y., Ravid, A. and Hochhauser, E. (2010) Dual Effect of Erythropoietin on Liver Protection and Regeneration after Subtotal Hepatectomy in Rats. Liver Transplantation, 16, 631-638.
[11] Lewis, L.D. (2004) Preclinical and Clinical Studies: A Preview of Potential Future Applications of Erythropoietic Agents. Seminars in Hematology, 41, 17-25.
[12] Bogoyevitch, M.A. (2004) An Update on the Cardiac Effects of Erythropoietin Cardioprotection by Erythropoietin and the Lessons Learnt from Studies in Neuroprotection. Cardiovascular Research, 63, 208-216.
[13] Yang, C.W., Li, C., Jung, J.Y., Shin, S.J., Choi, B.S., Lim, S.W., Sun, B.K., Kim, Y.S., Kim, J., Chang, Y.S. and Bang, B.K. (2003) Preconditioning with Erythropoietin Protects against Subsequent Ischemia-Reperfusion Injury in Rat Kidney. FASEB Journal, 17, 1754-1755.
[14] Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., Salio, M., Cerami, A. and Brines, M. (2003) Recombinant Human Erythropoietin Protects the Myocardium from Ischemia-Reperfusion Injury and Promotes Beneficial Remodeling. Proceedings of the National Academy of Sciences of the United States of America, 100, 4802-4806.
[15] Erslev, A.J. (1991) Erythropoietin. New England Journal of Medicine, 324, 1339-1344.
[16] Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin. Results of a Combined Phase I and II Clinical Trial. New England Journal of Medicine, 316, 73-78.
[17] Siren, A.L. and Ehrenreich, H. (2001) Erythropoietin—A Novel Concept for Neuroprotection. European Archives of Psychiatry and Clinical Neuroscience, 251, 179-184.
[18] Grasso, G. (2001) Neuroprotective Effect of Recombinant Human Erythropoietin in Experimental Subarachnoid Hemorrahage. Journal of Neurosurgery, 45, 7-14.
[19] Taub, R. (2004) Liver Regeneration: From Myth to Mechanism. Nature Reviews Molecular Cell Biology, 5, 836-847.
[20] Clavien, P.A., Petrowsky, H., De Oliveira, M.L. and Graf, R. (2007) Strategies for Safer Liver Surgery and Partial Liver Transplantation. New England Journal of Medicine, 356, 1545-1559.
[21] Taub, R., Greenbaum, L.E. and Peng, Y. (1999) Transcriptional Regulatory Signals Define Cytokine-Dependent and Independent Pathways in Liver Regeneration. Seminars in Liver Disease, 19, 117-127.
[22] Greif, F., Ben-Ari, Z., Taya, R., Pappo, O., Kurtzwald, E., Cheporko, Y., Ravid, A. and Hochhauser, E. (2010) Dual Effect of Erythropoietin on Liver Protection and Regeneration after Subtotal Hepatectomy in Rats. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 16, 631-638.
[23] Schwabe, R.F., Bradham, C.A., Uehara, T., Hatano, E., Bennett, B.L., Schoonhoven, R. and Brenner, D.A. (2003) c-Jun-N-Terminal Kinase Drives Cyclin D1 Expression and Proliferation during Liver Regeneration. Hepatology, 37, 824-832.
[24] Luedde, T., Rodriguez, M.E., Tacke, F., Xiong, Y., Brenner, D.A. and Trautwein, C. (2003) p18INK4c Collaborates with Other CDK Inhibitory Proteins in the Regenerating Liver. Hepatology, 37, 833-841.
[25] Behrens, A., Sibilia, M., David, J.P., Muhle-Steinlein, U., Tronche, F., Schütz, G. and Wagner, E.F. (2002) Impaired Postnatal Hepatocyte Proliferation and Liver Regeneration in Mice Lacking c-Jun in the Liver. The EMBO Journal, 21, 1782-1790.
[26] Talarmin, H., Rescan, C., Cariou, S., Glaise, D., Zanninelli, G., Bilodeau, M., Loyer, P., Guguen-Guillouzo, C. and Baffet, G. (1999) The Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Cascade Activation Is a Key Signaling Pathway Involved in the Regulation of G1 Phase Progression in Proliferating Hepatocytes. Molecular and Cellular Biology, 19, 6003-6011.
[27] Sakamoto, T., Liu, Z., Murase, N., Ezure, T., Yokomuro, S., Poli, V. and Demetris, A.J. (1999) Mitosis and Apoptosis in the Liver of Interleukin-6-Deficient Mice after Partial Hepatectomy. Hepatology, 29, 403-411.
[28] Yoshida, N., Iwata, H., Yamada, T., Sekino, T., Matsuo, H., Shirahashi, K., Miyahara, T., Kiyama, S. and Takemura, H. (2007) Improvement of the Survival Rate after Rat Massive Hepatectomy Due to the Reduction of Apoptosis by Caspase Inhibitor. Journal of Gastroenterology and Hepatology, 22, 2015-2021.
[29] Neuman, M.G. (2001) Apoptosis in Diseases of the Liver. Critical Reviews in Clinical Laboratory Sciences, 38, 109-166.
[30] Kahn, D., Hickman, R., Terblanche, J. and von Sommoggy, S. (1988) Partial Hepatectomy and Liver Regeneration in Pigs—The Response to Different Resection Sizes. The Journal of Surgical Research, 45, 176-180.
[31] Bullwinkel, J., Baron-Lühr, B., Lüdemann, A., Wohlenberg, C., Gerdes, J. and Scholzen, T. (2006) Ki-67 Protein Is Associated with Ribosomal RNA Transcription in Quiescent and Proliferating Cells. Journal of Cellular Physiology, 206, 624-635.
[32] Koskinas, J., Petraki, K., Kavantzas, N., Rapti, I., Kountouras, D. and Hadziyannis, S. (2005) Hepatic Expression of the Proliferative Marker Ki-67 and p53 Protein in HBV or HCV Cirrhosis in Relation to Dysplastic Liver Cell Changes and Hepatocellular Carcinoma. Journal of Viral Hepatitis, 12, 635-641.
[33] Schmidt, M., Broll, R., Bruch, H. and Duchrow, M. (2002) The Proliferation Marker pKi-67 Becomes Masked to MIB-1 Staining after Expression of Its Tandem Repeats. Histochemistry and Cell Biology, 118, 415-422.
[34] Humar, A., Kosari, K., Sielaff, T.D., Glessing, B., Gomes, M., Dietz, C., Rosen, G., Lake, J. and Payne, W.D. (2004) Liver Regeneration after Adult Living Donor and Deceased Donor Split-Liver Transplants. Liver Transplantation, 10, 374-378.
[35] Pahlavan, P.S., Feldmann Jr., R.E., Zavos, C. and Kountouras, J. (2006) Prometheus’ Challenge: Molecular, Cellular and Systemic Aspects of Liver Regeneration. Journal of Surgical Research, 134, 238-251.
[36] Savino, R. and Ciliberto, G. (2004) A Paradigm Shift for Erythropoietin: No Longer a Specialized Growth Factor, but Rather an All-Purpose Tissue-Protective Agent. Cell Death & Differentiation, 11, S2-S4.
[37] Bockhorn, M., Fingas, C.D., Rauen, U., Canbay, A., Sotiropoulos, G.C., Frey, U., Sheu, S.Y., Wohlschlager, J., Broelsch, C.E. and Schlaak, J.F. (2008) Erythropoietin Treatment Improves Liver Regeneration and Survival in Rat Models of Extended Liver Resection and Living Donor Liver Transplantation. Transplantation, 86, 1578-1585.
[38] Klemm, K., Eipel, C., Cantré, D., Abshagen, K., Menger, M.D. and Vollmar, B. (2008) Multiple Doses of Erythropoietin Impair Liver Regeneration by Increasing TNF-Alpha, the Bax to Bcl-xL Ratio and Apoptotic Cell Death. PLoS ONE, 3, e3924.
[39] Katavetin, P., Tungsanga, K., Eiam-Ong, S. and Nangaku, M. (2007) Antioxidative Effects of Erythropoietin. Kidney International, 72, S10-S15.
[40] Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Rüther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, M. and Sirén, A.L. (2002) Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. Molecular Medicine, 8, 495-505.
[41] Schmeding, M., Boas-Knoop, S., Lippert, S., Ruehl, M., Somasundaram, R., Dagdelen, T., Neuhaus, P. and Neumann, U.P. (2008) Erythropoietin Promotes Hepatic Regeneration after Extended Liver Resection in Rats. Journal of Gastroenterology and Hepatology, 23, 1125-1131.
[42] Kahn, D., van Hoom-Hickman, R., Child, P. and Terblanche, J. (1984) Transhepatic Changes in Insulin and Glucagon Following Partial Hepatectomy in the Pig: The Effect of Hypoglycemia. Surgery, Gynecology & Obstetrics, 158, 475.
[43] Kahn, D., Stadler, J., Terblanche, J. and van Hoom-Hickman, R. (1980) Thymidine Kinase: An Inexpensive Index of Liver Regeneration in a Large Animal Model. Gastroenterology, 79, 907-911.
[44] Kahn, D., van Hoorn-Hickman, R. and Terblanche, J. (1984) Liver Blood Flow after Partial Hepatectomy in the Pig. Journal of Surgical Research, 37, 290-294.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.